HEALTH● LOW2h ago · Oct 2, 2026, 5:45 AM
19 . 3 % Weight Loss at Week 48 : Phase Ⅲ Data of Olatorepatide , Hansoh Dual ‑ Biased GLP ‑ 1 / GIP Agonist , Presented at EASD
prnewswire.com · United States · global
Phase III clinical trial data for Olatorepatide, a GLP-1/GIP agonist by Hansoh, showed significant weight loss at week 48 when presented at EASD. This represents a notable development in obesity treatment research.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapUnited States and nearby eventsMore from United StatesLatest stories and threat level
More from United States
POLITICS1h agoUnited States – Cameroon: Trump chooses the architect of his expulsion agreements as ambassador to YaoundéJeune AfriqueWORLD2h agoIn 1922, a Hawaiian family bought a remote Pacific atoll to harvest coconuts; then they sued the United States, rejected plans to build a casino and sold it for conservationClarínSCI & TECH5h agoEight hours and a historical record: SpaceX's express flight that broke all records in the United StatesClarínMILITARY10h agoUnited States reinforces its presence in the Middle East: sends 9,000 soldiers and a third aircraft carrier amid tension with IranClarín
More in Health
HEALTH1h ago Startling mental ill health rates in LGBTQI communitymandurahmail.com.au · AustraliaHEALTH2h agoSan Diego Personal Injury Law Firm Levinson Law Group Supports Tumor Research at Rady Children Hospitalphoenixherald.com · United StatesHEALTH2h agoPopularity of peptides at ASU raises questions about safety and health impactsstatepress.com · United StatesHEALTH3h agoMassive markup on high-cost drugs: Raids to continue, Karnataka writes to CentreThe Hindu